Skip to main content
Erschienen in: Osteoporosis International 8/2013

01.08.2013 | Original Article

Risk of fracture in patients with Parkinson’s disease

verfasst von: S. Pouwels, M. T. Bazelier, A. de Boer, W. E. J Weber, C. Neef, C. Cooper, F. de Vries

Erschienen in: Osteoporosis International | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Summary

The aim of the study was to determine fracture risk in incident Parkinson’s disease (PD) patients. This study showed that fracture risk assessment may be indicated among patients with PD, in particular when they have recently used selective serotonin re-uptake inhibitors or high-dose antipsychotics, or have a history of fracture, falling, low body mass index (BMI) or renal disease.

Introduction

PD is a movement disorder associated with falling and detrimental effects on bone. Both are recognized risk factors for fracture. Therefore, the aim was to determine fracture risk in incident PD patients stratified by treatment, severity, duration of disease and related comorbidities.

Methods

We conducted a retrospective cohort study using the UK General Practice Research Database (1987–2011). Each PD patient was matched by age, sex, calendar time and practice to a control patient without history of PD.

Results

We identified 4,687 incident PD patients. Compared to controls, a statistically significant increased risk was observed for any fracture (adjusted hazard ratio [AHR], 1.89; 95 % confidence interval [CI], 1.67–2.14), osteoporotic fracture (AHR, 1.99; 95 % CI, 1.72–2.30) and hip fracture (AHR 3.08; 95 % CI, 2.43–3.89). Fracture risk further increased with history of fracture, falling, low BMI, renal disease, antidepressant use and use of high-dose antipsychotics.

Conclusion

This study showed that incident PD patients have a statistically significant increased risk of fracture. Therefore, fracture risk assessment may be indicated among PD patients, who, besides the general risk factors for fracture, like increasing age and female gender, have recently used selective serotonin re-uptake inhibitors or high-dose antipsychotics or have a history of fracture, falling, low BMI or renal disease.
Literatur
1.
Zurück zum Zitat Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson’s disease. N Engl J Med 348:1356PubMedCrossRef Nussbaum RL, Ellis CE (2003) Alzheimer’s disease and Parkinson’s disease. N Engl J Med 348:1356PubMedCrossRef
2.
Zurück zum Zitat Burch D, Sheerin F (2005) Parkinson’s disease. Lancet 365(9459):622–627PubMed Burch D, Sheerin F (2005) Parkinson’s disease. Lancet 365(9459):622–627PubMed
3.
Zurück zum Zitat Pickering RM, Grimbergen YA, Rigney U, Ashburn A, Mazibrada G, Wood B, Gray P, Kerr G, Bloem BR (2007) A meta-analysis of six prospective studies of falling in Parkinson’s disease. Mov Disord 22(13):1892–1900PubMedCrossRef Pickering RM, Grimbergen YA, Rigney U, Ashburn A, Mazibrada G, Wood B, Gray P, Kerr G, Bloem BR (2007) A meta-analysis of six prospective studies of falling in Parkinson’s disease. Mov Disord 22(13):1892–1900PubMedCrossRef
4.
Zurück zum Zitat Wielinski CL, Erickson-Davis C, Wichmann R, Walde-Douglas M, Parashos SA (2005) Falls and injuries resulting from falls among patients with Parkinson’s disease and other Parkinsonian syndromes. Mov Disord 20:410–415 Wielinski CL, Erickson-Davis C, Wichmann R, Walde-Douglas M, Parashos SA (2005) Falls and injuries resulting from falls among patients with Parkinson’s disease and other Parkinsonian syndromes. Mov Disord 20:410–415
5.
Zurück zum Zitat Sato Y, Kikuyama M, Oizumi K (1997) High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 49:1273–1278PubMedCrossRef Sato Y, Kikuyama M, Oizumi K (1997) High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 49:1273–1278PubMedCrossRef
6.
Zurück zum Zitat Kao CH, Chen CC, Wang SJ, Chia LG (1994) Bone mineral density in patients with Parkinson’s disease measured by dual photon absorptiometry. Nucl Med Commun 15:173–177PubMedCrossRef Kao CH, Chen CC, Wang SJ, Chia LG (1994) Bone mineral density in patients with Parkinson’s disease measured by dual photon absorptiometry. Nucl Med Commun 15:173–177PubMedCrossRef
7.
Zurück zum Zitat Sato Y, Iwamoto J, Honda Y (2011) Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson’s disease. Parkinsonism Relat Disord 17(1):22–26PubMedCrossRef Sato Y, Iwamoto J, Honda Y (2011) Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson’s disease. Parkinsonism Relat Disord 17(1):22–26PubMedCrossRef
8.
Zurück zum Zitat Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 373(2055):2066, Review. Erratum in Lancet 2009;374(9691):684 Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 373(2055):2066, Review. Erratum in Lancet 2009;374(9691):684
9.
10.
Zurück zum Zitat Becker C, Brobert GP, Johansson S, Jick SS, Meier CR (2011) Risk of incident depression in patients with Parkinson disease in the UK. Eur J Neurol 18(3):448–453PubMedCrossRef Becker C, Brobert GP, Johansson S, Jick SS, Meier CR (2011) Risk of incident depression in patients with Parkinson disease in the UK. Eur J Neurol 18(3):448–453PubMedCrossRef
11.
Zurück zum Zitat Bolluk B, Ozel-Kizil ET, Akbostanci MC, Atbasoglu EC (2010) Social anxiety in patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 22(4):390–394PubMedCrossRef Bolluk B, Ozel-Kizil ET, Akbostanci MC, Atbasoglu EC (2010) Social anxiety in patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 22(4):390–394PubMedCrossRef
12.
Zurück zum Zitat Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P (2001) Risk of dementia in Parkinsons disease: a community-based, prospective study. Neurology 56(6):730–736PubMedCrossRef Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P (2001) Risk of dementia in Parkinsons disease: a community-based, prospective study. Neurology 56(6):730–736PubMedCrossRef
13.
Zurück zum Zitat Eng ML, Welty TE (2010) Management of hallucinations and psychosis in Parkinson’s disease. Am J Geriatr Pharmacother 8(4):316–330PubMedCrossRef Eng ML, Welty TE (2010) Management of hallucinations and psychosis in Parkinson’s disease. Am J Geriatr Pharmacother 8(4):316–330PubMedCrossRef
14.
Zurück zum Zitat Baker NL, Cook MN, Arrighi HM, Bullock R (2011) Hip fracture risk and subsequent mortality among Alzheimer’s disease patients in the United Kingdom, 1988-2007. Age Ageing 40(1):49–54PubMedCrossRef Baker NL, Cook MN, Arrighi HM, Bullock R (2011) Hip fracture risk and subsequent mortality among Alzheimer’s disease patients in the United Kingdom, 1988-2007. Age Ageing 40(1):49–54PubMedCrossRef
15.
Zurück zum Zitat van den Brand MW, Samson MM, Pouwels S, van Staa TP, Thio B, Cooper C, Leufkens HG, Egberts AC, Verhaar HJ, de Vries F (2009) Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 20(10):1705–1713PubMedCrossRef van den Brand MW, Samson MM, Pouwels S, van Staa TP, Thio B, Cooper C, Leufkens HG, Egberts AC, Verhaar HJ, de Vries F (2009) Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 20(10):1705–1713PubMedCrossRef
16.
Zurück zum Zitat Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F (2009) Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 20(9):1499–1506PubMedCrossRef Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F (2009) Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 20(9):1499–1506PubMedCrossRef
17.
Zurück zum Zitat Sato Y, Kaji M, Tsuru T, Oizumi K (2001) Risk factors for hip fracture among elderly patients with Parkinson’s disease. J Neurol Sci 182(2):89–93PubMedCrossRef Sato Y, Kaji M, Tsuru T, Oizumi K (2001) Risk factors for hip fracture among elderly patients with Parkinson’s disease. J Neurol Sci 182(2):89–93PubMedCrossRef
18.
Zurück zum Zitat Schneider JL, Fink HA, Ewing SK, Ensrud KE, Cummings SR (2008) Study of Osteoporotic Fractures (SOF) Research Group. The association of Parkinson’s disease with bone mineral density and fracture in older women. Osteoporos Int 19(7):1093–1097PubMedCrossRef Schneider JL, Fink HA, Ewing SK, Ensrud KE, Cummings SR (2008) Study of Osteoporotic Fractures (SOF) Research Group. The association of Parkinson’s disease with bone mineral density and fracture in older women. Osteoporos Int 19(7):1093–1097PubMedCrossRef
19.
Zurück zum Zitat Genever RW, Downes TW, Medcalf P (2005) Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing 34:21–24PubMedCrossRef Genever RW, Downes TW, Medcalf P (2005) Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing 34:21–24PubMedCrossRef
20.
Zurück zum Zitat Johnell O, Melton LJ III, Atkinson EJ, O’Fallon WM, Kurland LT (1992) Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing 21:32–38PubMedCrossRef Johnell O, Melton LJ III, Atkinson EJ, O’Fallon WM, Kurland LT (1992) Fracture risk in patients with parkinsonism: a population-based study in Olmsted County, Minnesota. Age Ageing 21:32–38PubMedCrossRef
21.
Zurück zum Zitat Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Orwoll ES, Ensrud KE (2008) Osteoporotic Fractures in Men (MrOS) Study Group. Association of Parkinson’s disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 19(9):1277–1282PubMedCrossRef Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Orwoll ES, Ensrud KE (2008) Osteoporotic Fractures in Men (MrOS) Study Group. Association of Parkinson’s disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study. Osteoporos Int 19(9):1277–1282PubMedCrossRef
22.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L (2007) Fracture risk associated with parkinsonism and anti-Parkinson drugs. Calcif Tissue Int 81:153–161PubMedCrossRef Vestergaard P, Rejnmark L, Mosekilde L (2007) Fracture risk associated with parkinsonism and anti-Parkinson drugs. Calcif Tissue Int 81:153–161PubMedCrossRef
23.
Zurück zum Zitat Arbouw ME, Movig KL, van Staa TP, Egberts AC, Souverein PC, de Vries F (2011) Dopaminergic drugs and the risk of hip or femur fracture: a population-based case–control study. Osteoporos Int 22(7):2197–2204PubMedCrossRef Arbouw ME, Movig KL, van Staa TP, Egberts AC, Souverein PC, de Vries F (2011) Dopaminergic drugs and the risk of hip or femur fracture: a population-based case–control study. Osteoporos Int 22(7):2197–2204PubMedCrossRef
24.
Zurück zum Zitat Walley T, Mantgani A (1997) The UK General Practice Research Database. Lancet 350:1097–1099PubMedCrossRef Walley T, Mantgani A (1997) The UK General Practice Research Database. Lancet 350:1097–1099PubMedCrossRef
25.
Zurück zum Zitat Van Staa TP, Abenhaim L (1994) The quality of information recorded on a UK database of primary care records: a study of hospitalization due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Saf 3:15–21CrossRef Van Staa TP, Abenhaim L (1994) The quality of information recorded on a UK database of primary care records: a study of hospitalization due to hypoglycemia and other conditions. Pharmacoepidemiol Drug Saf 3:15–21CrossRef
26.
Zurück zum Zitat Van Staa TP, Abenhaim L, Cooper C, Begaud B, Zhang B, Leufkens HG (2000) The use of a large pharmaco-epidemiological database to study exposure to oral glucocorticoids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 9:359–366PubMedCrossRef Van Staa TP, Abenhaim L, Cooper C, Begaud B, Zhang B, Leufkens HG (2000) The use of a large pharmaco-epidemiological database to study exposure to oral glucocorticoids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 9:359–366PubMedCrossRef
27.
Zurück zum Zitat Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417–427PubMedCrossRef Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417–427PubMedCrossRef
28.
Zurück zum Zitat Hoehn M, Yahr M (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442PubMedCrossRef Hoehn M, Yahr M (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442PubMedCrossRef
29.
Zurück zum Zitat NICE (2006) Parkinson’s disease. Diagnosis and management in primary and secondary care (NICE clinical guideline 35). National Collaborating Centre for Chronic Conditions, London NICE (2006) Parkinson’s disease. Diagnosis and management in primary and secondary care (NICE clinical guideline 35). National Collaborating Centre for Chronic Conditions, London
30.
Zurück zum Zitat Norwegian Institute of Public Health (2012) WHO International Working Group for drug statistics methodology. Norwegian Institute of Public Health, WHO International Working Group for drug statistics methodology. http://www.whocc.no/atcddd/. Accessed May 11, 2012 Norwegian Institute of Public Health (2012) WHO International Working Group for drug statistics methodology. Norwegian Institute of Public Health, WHO International Working Group for drug statistics methodology. http://​www.​whocc.​no/​atcddd/​. Accessed May 11, 2012
31.
Zurück zum Zitat Hernán MA, Logroscino G, Rodríguez LA (2004) A prospective study of alcoholism and the risk of Parkinson’s disease. J Neurol 251(7):vII14–vII17PubMedCrossRef Hernán MA, Logroscino G, Rodríguez LA (2004) A prospective study of alcoholism and the risk of Parkinson’s disease. J Neurol 251(7):vII14–vII17PubMedCrossRef
32.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L (2006) Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 17(6):807–816PubMedCrossRef Vestergaard P, Rejnmark L, Mosekilde L (2006) Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 17(6):807–816PubMedCrossRef
33.
Zurück zum Zitat Verdel BM, Souverein PC, Egberts TC, van Staa TP, Leufkens HG, de Vries F (2010) Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 47(3):604–609PubMedCrossRef Verdel BM, Souverein PC, Egberts TC, van Staa TP, Leufkens HG, de Vries F (2010) Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 47(3):604–609PubMedCrossRef
34.
Zurück zum Zitat Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N (1998) Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 351(9112):1303–1307PubMedCrossRef Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N (1998) Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 351(9112):1303–1307PubMedCrossRef
35.
Zurück zum Zitat de Vries F, Setakis E, Zhang B, van Staa TP (2010) Long-acting {beta}2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD. Eur Respir J 36(3):494–502PubMedCrossRef de Vries F, Setakis E, Zhang B, van Staa TP (2010) Long-acting {beta}2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD. Eur Respir J 36(3):494–502PubMedCrossRef
36.
Zurück zum Zitat Bazelier M, Gallagher A, van Staa T, Cooper C, Leufkens H, Vestergaard P, De Vries F (2011) Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs? Pharmacoepidemiology and Drug Safety 20:S26 Bazelier M, Gallagher A, van Staa T, Cooper C, Leufkens H, Vestergaard P, De Vries F (2011) Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs? Pharmacoepidemiology and Drug Safety 20:S26
37.
Zurück zum Zitat Iwamoto J, Takeda T, Matsumoto H (2011) Efficacy of oral bisphosphonates for preventing hip fracture in disabled patients with neurological diseases: a meta-analysis of randomized controlled trials among the Japanese population. Curr Med Res Opin 27(6):1141–1148PubMedCrossRef Iwamoto J, Takeda T, Matsumoto H (2011) Efficacy of oral bisphosphonates for preventing hip fracture in disabled patients with neurological diseases: a meta-analysis of randomized controlled trials among the Japanese population. Curr Med Res Opin 27(6):1141–1148PubMedCrossRef
Metadaten
Titel
Risk of fracture in patients with Parkinson’s disease
verfasst von
S. Pouwels
M. T. Bazelier
A. de Boer
W. E. J Weber
C. Neef
C. Cooper
F. de Vries
Publikationsdatum
01.08.2013
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 8/2013
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-013-2300-2

Weitere Artikel der Ausgabe 8/2013

Osteoporosis International 8/2013 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.